Advertisement
ORMP vs SDEV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and SDEV is a Hold.
ORMP in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 08, 2026
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where ORMP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Oscillator exited the oversold zone, 22 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 70 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ORMP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.535) is normal, around the industry mean (3.035). P/E Ratio (0.962) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.245) settles around the average of (133.535) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SDEV in +188.80% Uptrend, rising for three consecutive days on October 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SDEV advanced for three days, in 193 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In 59 of 73 cases where SDEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for SDEV moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 17 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SDEV as a result. In 68 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SDEV turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 34 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SDEV moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SDEV crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SDEV broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 6 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. SDEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.398) is normal, around the industry mean (2.393). P/E Ratio (-0.160) is within average values for comparable stocks, (-3.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.272) among similar stocks. P/S Ratio (16.639) is also within normal values, averaging (15.798).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
ORMP | SDEV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 15 | 6 | |
PRICE GROWTH RATING 1..100 | 44 | 74 | |
P/E GROWTH RATING 1..100 | 93 | 97 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as SDEV (83) in the Biotechnology industry. This means that ORMP’s stock grew similarly to SDEV’s over the last 12 months.
SDEV's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that SDEV’s stock grew similarly to ORMP’s over the last 12 months.
SDEV's SMR Rating (6) in the Biotechnology industry is in the same range as ORMP (15) in the Pharmaceuticals Other industry. This means that SDEV’s stock grew similarly to ORMP’s over the last 12 months.
ORMP's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as SDEV (74) in the Biotechnology industry. This means that ORMP’s stock grew similarly to SDEV’s over the last 12 months.
ORMP's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as SDEV (97) in the Biotechnology industry. This means that ORMP’s stock grew similarly to SDEV’s over the last 12 months.
| ORMP | SDEV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 73% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 71% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 78% | 4 days ago 90% |
| MACD ODDS (%) | N/A | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 78% | 4 days ago 85% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 90% |
| Advances ODDS (%) | 22 days ago 82% | 25 days ago 83% |
| Declines ODDS (%) | 5 days ago 81% | 7 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 88% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 82% | 4 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORMP’s FA Score shows that 1 FA rating(s) are green while SDEV’s FA Score has 1 green FA rating(s).
- ORMP’s FA Score: 1 green, 4 red.
- SDEV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORMP’s TA Score shows that 4 TA indicator(s) are bullish while SDEV’s TA Score has 3 bullish TA indicator(s).
- ORMP’s TA Score: 4 bullish, 5 bearish.
- SDEV’s TA Score: 3 bullish, 7 bearish.
Price Growth
ORMP (@Biotechnology) experienced а +1.47% price change this week, while SDEV (@Investment Managers) price change was +13.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.20%. For the same industry, the average monthly price growth was -13.19%, and the average quarterly price growth was -12.91%.
The average weekly price growth across all stocks in the @Investment Managers industry was -0.35%. For the same industry, the average monthly price growth was -8.22%, and the average quarterly price growth was -1.32%.
Reported Earning Dates
ORMP is expected to report earnings on Nov 12, 2026.
SDEV is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (+4.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Investment Managers (-0.35% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
Advertisement
ORMP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.
| Ticker / NAME | Correlation To ORMP | 1D Price Change % | ||
|---|---|---|---|---|
| ORMP | 100% | +0.24% | ||
| DRTS - ORMP | 53% Loosely correlated | +2.02% | ||
| INO - ORMP | 44% Loosely correlated | +6.94% | ||
| MBIO - ORMP | 44% Loosely correlated | +0.22% | ||
| CGEM - ORMP | 42% Loosely correlated | -3.69% | ||
| CGEN - ORMP | 41% Loosely correlated | -1.02% | ||
More | ||||
SDEV and
Correlation & Price change
A.I.dvisor indicates that over the last year, SDEV has been loosely correlated with ALP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SDEV jumps, then ALP could also see price increases.
| Ticker / NAME | Correlation To SDEV | 1D Price Change % | ||
|---|---|---|---|---|
| SDEV | 100% | -9.09% | ||
| ALP - SDEV | 38% Loosely correlated | +1.68% | ||
| ALT - SDEV | 30% Poorly correlated | -2.30% | ||
| ORMP - SDEV | 29% Poorly correlated | +0.24% | ||
| RPC - SDEV | 28% Poorly correlated | -2.03% | ||
| RVMD - SDEV | 28% Poorly correlated | -0.37% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FTMN | 8.43 | 0.01 | +0.12% |
| Franklin Minnesota Municipal Income ETF (FTMN) | |||
| BMEZ | 16.76 | -0.02 | -0.12% |
| BlackRock Health Sciences Term Trust | |||
| SAY | 25.25 | -0.05 | -0.20% |
| Saratoga Investment Corp | |||
| FINT | 35.52 | -0.08 | -0.21% |
| Frontier Asset Total International Equity ETF | |||
| AMDD | 26.24 | -0.43 | -1.61% |
| Direxion Daily AMD Bear 1X ETF (AMDD) | |||